II. Indications

III. Mechanism

  1. Inhibits platelet aggregation

IV. Dosing: Abciximab (ReoPro)

  1. Load: 0.25 mg/kg IV bolus
  2. Infuse: 0.125 ug/kg/min up to 10 ug/min IV x12 hours

V. Dosing: Eptifibatide (Integrilin)

  1. Acute Coronary Syndrome
    1. Load: 180 ug/kg
    2. Infuse: 2 ug/kg/min IV x72 hours
  2. Angioplasty
    1. Load: 135 ug/kg IV before procedure
    2. Infuse: 0.5 ug/kg/min IV x24 hours

VI. Dosing: Tirofiban (Aggrastat)

  1. Load: 0.4 ug/kg/min for 30 minutes
  2. Infuse: 0.1 ug/kg/min
  3. Infusion duration
    1. Acute Coronary Syndrome: 48 to 108 hours
    2. Angioplasty: 12 to 24 hours

Images: Related links to external sites (from Bing)

Related Studies (from Trip Database) Open in New Window

Ontology: tirofiban (C0247025)

Concepts Pharmacologic Substance (T121) , Organic Chemical (T109)
MSH C078823
SnomedCT 108981004, 386953003
LNC LP171644-0
English N-(butylsulfonyl)-O-(4-(4-piperidyl)butyl)-L-tyrosine, tirofiban, tirofiban (medication), tirofiban [Chemical/Ingredient], TIROFIBAN, Tirofiban (product), Tirofiban (substance), Tirofiban
Spanish tirofibán (producto), tirofibán (sustancia), tirofibán

Ontology: eptifibatide (C0253563)

Definition (NCI) A cyclical heptapeptide with anticoagulant activity. Eptifibatide selectively and reversibly binds to and blocks the platelet glycoprotein IIb/IIIa receptor. This prevents the binding of fibrinogen, von Willebrand factor, and other adhesive ligands and leads to an inhibition of platelet aggregation and prevents thrombus development.
Concepts Pharmacologic Substance (T121) , Amino Acid, Peptide, or Protein (T116)
MSH C086648
SnomedCT 116065005, 386998009
LNC LP171395-9
English L-Cysteinamide, N6-(aminoiminomethyl)-N2-(3-mercapto-1-oxopropyl)-L-lysylglycyl-L-alpha-aspartyl-L-tryptophy-L-prolyl-, cyclic(1-6)-disulfide, eptifibatide, eptifibatide (medication), eptifibatide [Chemical/Ingredient], Eptifibatide (product), Eptifibatide (substance), Eptifibatide, epifibatide, epifibratide, EPTIFIBATIDE
Japanese エプチフィバチド
Spanish eptifibatida (producto), eptifibatida (sustancia), eptifibatida

Ontology: abciximab (C0288672)

Definition (NCI) A Fab fragment of the chimeric monoclonal antibody 7E3 and inhibitor of the glycoprotein (GP) IIb/IIIa receptor, that blocks platelet aggregation. Abciximab binds to the GP IIb/IIIa receptor on the platelet membrane, which inhibits the binding of fibrinogen to the GP IIb/IIIa receptor. This prevents both platelet aggregation and thrombus formation.
Concepts Immunologic Factor (T129) , Amino Acid, Peptide, or Protein (T116) , Pharmacologic Substance (T121)
MSH C085843
SnomedCT 391697004, 386951001, 108974006
LNC LP171382-7
English abciximab, abciximab (medication), MoAb 7E3, Chimeric 7E3 Fab, abciximab [Chemical/Ingredient], Abciximab - chemical (substance), Abciximab - chemical, Abciximab, Abciximab (product), Abciximab (substance), c7E3 Fab, chimeric 7E3 Fab, ABCIXIMAB
Spanish abciximab (producto), abciximab (sustancia), abciximab

Ontology: ReoPro (C0592046)

Concepts Pharmacologic Substance (T121) , Amino Acid, Peptide, or Protein (T116)
MSH C085843
English ReoPro, Reopro, reopro, Eli Lilly brand of abciximab, Lilly brand of abciximab

Ontology: Aggrastat (C0656369)

Concepts Pharmacologic Substance (T121) , Organic Chemical (T109)
MSH C078823
English Aggrastat, aggrastat, Cahill May Roberts brand of tirofiban hydrochloride monohydrate, MSD brand of tirofiban hydrochloride monohydrate, Merck Frosst brand of tirofiban hydrochloride monohydrate, Merck Sharp & Dohme brand of tirofiban hydrochloride monohydrate, Merck brand of tirofiban hydrochloride monohydrate, Agrastat

Ontology: Integrilin (C0950902)

Concepts Pharmacologic Substance (T121) , Amino Acid, Peptide, or Protein (T116)
MSH C086648
English Integrilin, eptifibatide (Integrilin), Integrelin, Pfizer brand of eptifibatide, GlaxoSmithKline UK brand of eptifibatide, integrelin, integrilin, Cor brand of eptifibatide, Essex brand of eptifibatide, Key brand of eptifibatide